Abstract:Purpose: To validate the ability of theranostic imaging biomarkers in assessing corneal cross-linking (CXL) efficacy in flattening the maximum keratometry (Kmax) index. Design: Prospective, randomized, multicenter, masked clinical trial (ClinicalTrails.gov identifier, NCT05457647). Participants: Fifty patients with progressive keratoconus. Intervention: Participants were stratified to undergo epithelium-off (25 eyes) and epithelium-on (25 eyes) CXL protocols using an ultraviolet A (UV-A) medical device with theranostic software. The device controlled UV-A light both for performing CXL and assessing the corneal riboflavin concentration (riboflavin score) and treatment effect (theranostic score). A 0.22% riboflavin formulation was applied onto the cornea for 15 minutes and 20 minutes in epithelium-off and epithelium-on protocols, respectively. All eyes underwent 9 minutes of UV-A irradiance at 10 mW/cm2. Main outcome measures: The primary outcome measure was validation of the combined use of theranostic imaging biomarkers through measurement of their accuracy (proportion of correctly classified eyes) and precision (positive predictive value) to classify eyes correctly and predict a Kmax flattening at 1 year after CXL. Other outcome measures included change in Kmax, endothelial cell density, uncorrected and corrected distance visual acuity, manifest spherical equivalent refraction and central corneal thickness 1 year after CXL. Results: Accuracy and precision of the theranostic imaging biomarkers in predicting eyes that had >0.1 diopter (D) of Kmax flattening at 1 year were 91% and 95%, respectively. The Kmax value significantly flattened by a median of -1.3 D (IQR, -2.11 to -0.49 D; P < 0.001); both the uncorrected and corrected distance visual acuity improved by a median of -0.1 logarithm of the minimum angle of resolution (logMAR; IQR, -0.3 to 0.0 logMAR [P < 0.001] and -0.2 to 0.0 logMAR [P < 0.001], respectively). No significant changes in endothelial cell density (P = 0.33) or central corneal thickness (P = 0.07) were noted 1 year after surgery. Conclusions: The study demonstrated the efficacy of integrating theranostics in a UV-A medical device for the precise and predictive treatment of keratoconus with epithelium-off and epithelium-on CXL protocols. Concentration of riboflavin and its UV-A light mediated photoactivation in the cornea are the primary factors determining CXL efficacy. Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Real-time monitoring of riboflavin concentration using different clinically available ophthalmic formulations for epi-off and epi-on corneal cross-linking

Predicting corneal cross-linking treatment efficacy with real-time assessment of corneal riboflavin concentration

Spatial targeted delivery of riboflavin with a controlled corneal iontophoresis delivery system in theranostic‐guided UV‐A light photo‐therapy

Non-invasive detection of nanoscale structural changes in cornea associated with cross-linking treatment

Assessment of the Predictive Ability of Theranostics for Corneal Cross-linking in Treating Keratoconus: A Randomized Clinical Trial

Responsive porous microneedles with riboflavin ocular microinjection capability for facilitating corneal crosslinking

A nanotechnology‐based solution for epi‐on corneal cross‐linking

An in vitro investigation into the impact of corneal rinsing on riboflavin/UVA corneal cross-linking

Chemically-Boosted Corneal Cross-Linking for the Treatment of Keratoconus through a Riboflavin 0.25% Optimized Solution with High Superoxide Anion Release

Epi-off riboflavin with vitamin E TPGS (Ribocross®) cross-linking: one-year outcome

A Novel Riboflavin Formulation for Corneal Delivery Without Damaging Epithelial Cells

Model Systems for Evidencing the Mediator Role of Riboflavin in the UVA Cross-Linking Treatment of Keratoconus

Topographic Outcomes in Keratoconus Surgery: Epi-on versus Epi-off Iontophoresis Corneal Collagen Cross-Linking

RiTe conjugate mediated corneal collagen crosslinking, a novel therapeutic intervention for keratoconus – In vitro and in vivo study

[The Clinical Study of Corneal Cross-Linking with Hypo-Osmolar Riboflavin Solution in Thin Keratoconic Corneas].

[Advanced Research in the Safety of UVA-riboflavin Cross-Linking for Strengthening Corneal and Scleral Tissue].

Customized Corneal Cross‐Linking with Microneedle‐Mediated Riboflavin Delivery for Keratoconus Treatment (Adv. Mater. 46/2024)

Crosslinking with UV-A and riboflavin in progressive keratoconus: From laboratory to clinical practice - Developments over 25 years

Customized Corneal Cross-Linking with Microneedle-Mediated Riboflavin Delivery for Keratoconus Treatment

Rates of infectious keratitis and other ocular surface adverse events in corneal cross-linking for keratoconus and corneal ectasias performed in an office-based setting: a retrospective cohort study

Molecular and cellular mechanisms of ultraviolet corneal crosslinking